10 apr: Tre effektive måder at reducere din formue på
12 apr: Minimalistisk pragtvilla i Sverige
11-04-2012 23:54:00

UPDATE: Quest Diagnostics Names Rusckowski As President, CEO

Relateret indhold

--Quest names Philips executive as new CEO

--Stephen Rusckowski's appointment effective May 1

--Change could mark new course for Quest

(Adds analyst comments, updated share price, other information, in the second, fourth and fifth paragraphs.)

By Anjali Athavaley and Nathalie Tadena

Of DOW JONES NEWSWIRES

NEW YORK -(Dow Jones)- Quest Diagnostics Inc. (DGX) named Royal Philips Electronics NV (PHG, PHIA.AE) executive Stephen Rusckowski as its new president and chief executive, ending a six-month search for a successor to current CEO Surya Mohapatra.

Rusckowski's appointment is effective May 1, and he will join the company's board. Rusckowski has served as CEO of Philips Healthcare, Royal Philips' largest unit, since 2006. During his tenure, revenue at the unit increased to about EUR9 billion and 39% of Royal Philips' total revenue in 2011 from about EUR6B and 21% of revenue in 2005.

The management change could mark a new course for the company. Some decisions Quest made under Mohapatra--such as the acquisition of diagnostics company AmeriPath Inc. and an expansion into India--have been criticized by analysts.

"We knew this was going to get announced any day," said Art Henderson, health-care analyst at Jefferies & Co. "The investment community wasn't sure who the candidate would be. Who they have chosen is obviously somebody who was pretty instrumental in the growth at Philips."

Quest shares rose 1% to $60.20 in after-hours trading Wednesday. The stock is up 2.6% this year.

Quest, the largest diagnostic-testing company in the U.S. by revenue, had been hurt by a decline in doctor-office visits as consumers have reined in their health-care spending since the recession. Last year, the company unveiled a restructuring initiative to reduce its costs by $500 million over the next three years to help it meet profit targets. In October, the company initiated a search for a replacement for Mohapatra, who held the titles of chairman, president and CEO.

Quest also appointed lead director Daniel C. Stanzione as its new non-executive chairman.

"Steve Rusckowski is uniquely qualified to be chief executive officer of Quest Diagnostics," Stanzione said. "He has built an enviable track record in health care by successfully driving growth, both organically and through disciplined, effective acquisitions. His emphasis on operational excellence has enabled him to deliver consistently impressive results."

In January, Quest reported its fourth-quarter earnings rose 14% as the company saw higher testing revenue and improved margins.

-By Anjali Athavaley and Nathalie Tadena, Dow Jones Newswires; 212-416-4912; anjali.athavaley@dowjones.com

(END) Dow Jones Newswires

April 11, 2012 17:54 ET (21:54 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Nordea/Nykredit: Mindre gevinst ved flytningen betyder ikke meget

16-02-2018 16:17:10
Ændringen i besparelserne ved Nordeas flytning til Finland fra Sverige betyder ikke frygtelig meget.Det vurderer analytiker ved Nykredit Markets Ricky Steen Rasmussen.Forventningerne til besparelserne i forbindelse med flytningen til Finland er blevet justeret til 0,9-1,2 mia. euro fra 1,1-1,3 mia. euro. Det oplyste Nordea i en meddelelse til fondsbørsen fredag eftermiddag.- Jeg ser ikke særlig st..

Nordea venter færre besparelser ved flytning til Finland

16-02-2018 14:18:54
Efter nøje beregninger er Nordea kommet frem til, at den forestående flytning af hovedsædet til Finland fra Sverige giver en mindre økonomisk gevinst end hidtil antaget.Nu venter den skandinaviske storbank, at nettonutidsværdien af de samlede besparelser på afviklingsgebyrer, indskydergarantier og andre midlertidige effekter af flytningen af hovedsædet udgør cirka 0,9-1,2 mia. euro. Tidligere regn..

Aktier/middag: Bred funderet opgang er modreaktion på korrektion

16-02-2018 11:19:57
De ledende danske aktier ligger fredag middag alle i grønt uden deciderede selskabsspecifikke faktorer som forklaring på de enkelte aktiers bevægelser.I toppen ligger Novozymes, Novo Nordisk og DSV.C25-indekset ligger fredag middag med en stigning på 1,9 pct. i 1142,72. Det er tredje dag i træk med løft, og indekset er indtil videre steget fire af de seneste fem handelsdage og små 5 pct. siden sid..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Hartmann: Direktør Ulrik Kolding Hartvig død efter cykelulykke
2
Briter har 10 dage til at bruge 1,8 milliarder kroner - citat
3
Lettisk nationalbankdirektør er anholdt af korruptionspoliti
4
Briterne ønsker sikkerhedstraktat med EU inden 2019
5
Japans eksport steg noget mere end ventet i januar

Relaterede aktiekurser

Quest Diagnostics Incorp.. 104,53 0,0% Aktiekurs uændret
Philips KON 31,52 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
19. februar 2018 08:38:12
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180209.1 - EUROWEB6 - 2018-02-19 08:38:12 - 2018-02-19 08:38:12 - 1 - Website: OKAY